|
|
|
|
|
News and Articles on Open Label Study
Device blocking stomach nerve signals shows promise in obesity Jun 27, 2008
"In an open label study such as the one being published this month, there is always potential for the device to 'work' because patients believe it will," he explains. "In the next study, which has already begun, all patients will have the device implanted, but one-third will not have it turned on during the first year of the study, so that after meals, it won't be blocking the nerve signals; this is called 'sham' treatment. Neither the patients nor their doctors will know whether the blocking... (EurekAlert!)
Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus(R) Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones Jun 24, 2007
"For example, the ongoing ORIGIN study will examine long-term cardiovascular outcomes in more than 12,000 diabetic and pre-diabetic patients. The ORIGIN study is now fully enrolled and we expect its results in 2010." About Poster 1 (Change in Lipid Variables With Insulin Glargine (GLAR) vs Pioglitazone (PIO) Added to a Sulfonylurea (SU) or Metformin (MET) - Abstract # 0890-P) This randomized, multicenter, 48-week, parallel-group, open label study compared the lipid changes observed with... (PR Newswire)
Abbott Announces Positive Six-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent Mar 25, 2007
Abbott's Bioabsorbable Stent Technology Holds Promise as Future-Generation Treatment Option for Physicians Treating Patients with Coronary Artery Disease ABBOTT PARK, Ill. March 24 /PRNewswire-FirstCall/ -- Abbott today announced positive results from ABSORB, the world's first clinical trial evaluating the overall safety and performance of a fully bioabsorbable drug- eluting stent platform for the treatment of coronary artery disease. (PR Newswire)
Stem Cell Therapeutics Corp. Announces Entering into Agreement to Support a Phase IIa Clinical Safety Study Apr 25, 2006
Patient screening for this open label study, expected to enrol approximately 12 subjects, is anticipated to begin in the near future. This Phase IIa safety trial is designed to explore the safety profile of NTx(TM)- 265, a regimen of two currently marketed drugs, in new stroke patients. (Canada Newswire)
[ Terms Of Use | Privacy | About ]
©1998-2008 SurfWax, Inc.
All rights reserved. Patents pending.
|
|
|
Copyright SurfWax, Inc. 2008
|
|
